FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283016770> ?p ?o ?g. }

• W4283016770 endingPage "1408" @default.
• W4283016770 startingPage "1395" @default.
• W4283016770 abstract "The efficacy and safety of switching to insulin glargine 300 U/mL (Gla-300) in type 2 diabetes mellitus (T2DM) uncontrolled on basal insulin (BI) has been demonstrated in the North American and Western European populations; however, there is limited data from other geographical regions with different ethnicities. The ARTEMIS-DM study aimed to evaluate the efficacy and safety of Gla-300 in people with T2DM uncontrolled on BI from Asia, Latin America and Middle East Africa.The ARTEMIS-DM was a 26-week, prospective, interventional, single-arm, phase IV study (NCT03760991). Adults with T2DM previously uncontrolled (glycated haemoglobin [HbA1c] 7.5-10%) on BI were switched to Gla-300. The primary endpoint was change in HbA1c from baseline to 26 weeks. Key secondary endpoints were changes in HbA1c (week 12), fasting plasma glucose (FPG), self-monitored plasma glucose (SMPG) and BI dose from baseline to week 26. The safety and tolerability of Gla-300 were also assessed.A total of 372 (50% male) participants were included, with mean (standard deviation [SD]) age 60.9 (10.0) years, duration of diabetes 13.11 (7.48) years and baseline HbA1c 8.67 (0.77)% (71.22 [8.44] mmol/mol). A total of 222 (59.7%) participants were using insulin glargine 100 U/mL and 107 (28.8%) were using neutral protamine Hagedorn insulin as previous BI. There were clinically significant reductions in mean HbA1c (- 0.82%; primary endpoint), FPG and SMPG levels at week 26. With a pre-defined titration algorithm, mean Gla-300 dose increased from 27.48 U (0.35 U/kg) at baseline to 39.01 U (0.50 U/kg) at week 26. Hypoglycaemia events occurred in 20.4% of the participants; 1 (0.3%) participant had a severe hypoglycaemia event.In people with T2DM uncontrolled on previous BI, switching to Gla-300 with optimal titration guided by an algorithm was associated with improved glycaemic control and low incidence of hypoglycaemia across multiple geographic regions.NCT03760991.The online version contains supplementary material available at 10.1007/s13300-022-01271-7." @default.
• W4283016770 created "2022-06-18" @default.
• W4283016770 creator A5020344477 @default.
• W4283016770 creator A5023167476 @default.
• W4283016770 creator A5026007773 @default.
• W4283016770 creator A5038729212 @default.
• W4283016770 creator A5041274229 @default.
• W4283016770 creator A5079922162 @default.
• W4283016770 creator A5082246827 @default.
• W4283016770 creator A5090518763 @default.
• W4283016770 date "2022-06-17" @default.
• W4283016770 modified "2023-10-10" @default.
• W4283016770 title "Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study" @default.
• W4283016770 cites W1726580060 @default.
• W4283016770 cites W1849264946 @default.
• W4283016770 cites W1996259073 @default.
• W4283016770 cites W2056526409 @default.
• W4283016770 cites W2100633491 @default.
• W4283016770 cites W2160088494 @default.
• W4283016770 cites W2575842264 @default.
• W4283016770 cites W2726082861 @default.
• W4283016770 cites W2743088090 @default.
• W4283016770 cites W2775100391 @default.
• W4283016770 cites W2777315381 @default.
• W4283016770 cites W2822926293 @default.
• W4283016770 cites W2883817914 @default.
• W4283016770 cites W2894993577 @default.
• W4283016770 cites W2901044756 @default.
• W4283016770 cites W2914739803 @default.
• W4283016770 cites W2972869264 @default.
• W4283016770 cites W2990402465 @default.
• W4283016770 cites W2996274251 @default.
• W4283016770 cites W2998251647 @default.
• W4283016770 cites W2998638642 @default.
• W4283016770 cites W3042962946 @default.
• W4283016770 cites W3066615100 @default.
• W4283016770 cites W3175170798 @default.
• W4283016770 cites W3177047784 @default.
• W4283016770 cites W4229367629 @default.
• W4283016770 cites W4230570152 @default.
• W4283016770 doi "https://doi.org/10.1007/s13300-022-01271-7" @default.
• W4283016770 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35730004" @default.
• W4283016770 hasPublicationYear "2022" @default.
• W4283016770 type Work @default.
• W4283016770 citedByCount "0" @default.
• W4283016770 crossrefType "journal-article" @default.
• W4283016770 hasAuthorship W4283016770A5020344477 @default.
• W4283016770 hasAuthorship W4283016770A5023167476 @default.
• W4283016770 hasAuthorship W4283016770A5026007773 @default.
• W4283016770 hasAuthorship W4283016770A5038729212 @default.
• W4283016770 hasAuthorship W4283016770A5041274229 @default.
• W4283016770 hasAuthorship W4283016770A5079922162 @default.
• W4283016770 hasAuthorship W4283016770A5082246827 @default.
• W4283016770 hasAuthorship W4283016770A5090518763 @default.
• W4283016770 hasBestOaLocation W42830167701 @default.
• W4283016770 hasConcept C126322002 @default.
• W4283016770 hasConcept C134018914 @default.
• W4283016770 hasConcept C168563851 @default.
• W4283016770 hasConcept C197934379 @default.
• W4283016770 hasConcept C203092338 @default.
• W4283016770 hasConcept C2777180221 @default.
• W4283016770 hasConcept C2778375690 @default.
• W4283016770 hasConcept C2779306644 @default.
• W4283016770 hasConcept C2779920387 @default.
• W4283016770 hasConcept C2910068830 @default.
• W4283016770 hasConcept C555293320 @default.
• W4283016770 hasConcept C71924100 @default.
• W4283016770 hasConceptScore W4283016770C126322002 @default.
• W4283016770 hasConceptScore W4283016770C134018914 @default.
• W4283016770 hasConceptScore W4283016770C168563851 @default.
• W4283016770 hasConceptScore W4283016770C197934379 @default.
• W4283016770 hasConceptScore W4283016770C203092338 @default.
• W4283016770 hasConceptScore W4283016770C2777180221 @default.
• W4283016770 hasConceptScore W4283016770C2778375690 @default.
• W4283016770 hasConceptScore W4283016770C2779306644 @default.
• W4283016770 hasConceptScore W4283016770C2779920387 @default.
• W4283016770 hasConceptScore W4283016770C2910068830 @default.
• W4283016770 hasConceptScore W4283016770C555293320 @default.
• W4283016770 hasConceptScore W4283016770C71924100 @default.
• W4283016770 hasFunder F4320307781 @default.
• W4283016770 hasIssue "7" @default.
• W4283016770 hasLocation W42830167701 @default.
• W4283016770 hasLocation W42830167702 @default.
• W4283016770 hasLocation W42830167703 @default.
• W4283016770 hasOpenAccess W4283016770 @default.
• W4283016770 hasPrimaryLocation W42830167701 @default.
• W4283016770 hasRelatedWork W1983641721 @default.
• W4283016770 hasRelatedWork W1995945960 @default.
• W4283016770 hasRelatedWork W2026226896 @default.
• W4283016770 hasRelatedWork W2032033851 @default.
• W4283016770 hasRelatedWork W2041678535 @default.
• W4283016770 hasRelatedWork W2066345847 @default.
• W4283016770 hasRelatedWork W2089387278 @default.
• W4283016770 hasRelatedWork W2095179743 @default.
• W4283016770 hasRelatedWork W2130904138 @default.
• W4283016770 hasRelatedWork W4230655895 @default.
• W4283016770 hasVolume "13" @default.
• W4283016770 isParatext "false" @default.

• next